To hear about similar clinical trials, please enter your email below
Trial Title:
99mTc-CNDG SPECT/CT in Brain Tumors
NCT ID:
NCT06362304
Condition:
Intracranial Tumor
Conditions: Official terms:
Brain Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
99mTc-CNDG SPECT/CT
Description:
FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
Arm group label:
intracranial tumor
Summary:
The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of
brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:
1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG?
2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?
Participants will:
Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain
pathological diagnosis by surgery or biopsy as the gold standard.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patients with clinical diagnosis of brain tumor;
- Be at least 18 years old;
- The final pathological results could be obtained by surgery or biopsy;
- Informed consent and the ability to be followed up;
- Those who did not meet the exclusion criteria.
Exclusion Criteria:
- Insulin-dependent diabetes mellitus or fasting blood glucose >7 mmol/L before
99mTc-CNDG injection;
- Severe liver or kidney disease (serum creatinine level >3.0mg/dL or any liver enzyme
level ≥ 5 times the upper limit of normal);
- Severe hypersensitivity or hypersensitivity to radiocontrast agents;
- Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
- Patients receiving radiotherapy and chemotherapy;
- Being pregnant or breastfeeding.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
April 2024
Completion date:
April 2025
Lead sponsor:
Agency:
Peking Union Medical College Hospital
Agency class:
Other
Source:
Peking Union Medical College Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06362304
